Pesquisas alternativas:
last phase » blast phase (Expandir a Pesquisa), yeast phase (Expandir a Pesquisa)
gait » gain (Expandir a Pesquisa)
last phase » blast phase (Expandir a Pesquisa), yeast phase (Expandir a Pesquisa)
gait » gain (Expandir a Pesquisa)
1
Por Demetri, George D, Reichardt, Peter, Kang, Yoon-Koo, Blay, Jean-Yves, Rutkowski, Piotr, Gelderblom, Hans, Hohenberger, Peter, Leahy, Michael, von Mehren, Margaret, Joensuu, Heikki, Badalamenti, Giuseppe, Blackstein, Martin, Cesne, Axel Le, Schöffski, Patrick, Maki, Robert G, Bauer, Sebastian, Nguyen, Binh Bui, Xu, Jianming, Nishida, Toshirou, Chung, John, Kappeler, Christian, Kuss, Iris, Laurent, Dirk, Casali, Paolo
Publicado em 2012
“... and safety of regorafenib in patients with metastatic and/or unresectable GIST progressing after failure...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
Por Kawai, Yohko, Fuji, Takeshi, Fujita, Satoru, Kimura, Tetsuya, Ibusuki, Kei, Abe, Kenji, Tachibana, Shintaro
Publicado no Thromb J (2016)
“... with enoxaparin on key coagulation biomarkers and present pooled primary efficacy and safety results from phase 3...”Publicado no Thromb J (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Keshuang TANG
Publicado em 2008-01-01
Assuntos:
“...Intersection safety...”Publicado em 2008-01-01
Obter o texto integral
Artigo
4
Por Langley, Joanne M., Carmona Martinez, Alfonso, Chatterjee, Archana, Halperin, Scott A., McNeil, Shelly, Reisinger, Keith S., Aggarwal, Naresh, Huang, Li-Min, Peng, Ching-Tien, Garcia-Sicilia, José, Salamanca de la Cueva, Ignacio, Cabañas, Fernando, Treviño-Garza, Consuelo, Rodríguez-Weber, Miguel Angel, de la O, Manuel, Chandrasekaran, Vijayalakshmi, Dewé, Walthère, Liu, Aixue, Innis, Bruce L., Jain, Varsha K.
Publicado em 2013
“... strains (A/H3N2 and A/H1N1) based on hemagglutination-inhibition (HI) antibodies 28 days after last...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
“... of pregnancy, the postoperative full term delivery rate, fetal salvage rate (if pregnancy lasted ≥ 14 weeks...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping...
Por Burri, Christian, Yeramian, Patrick D., Allen, James L., Merolle, Ada, Serge, Kazadi Kyanza, Mpanya, Alain, Lutumba, Pascal, Mesu, Victor Kande Betu Ku, Bilenge, Constantin Miaka Mia, Lubaki, Jean-Pierre Fina, Mpoto, Alfred Mpoo, Thompson, Mark, Munungu, Blaise Fungula, Manuel, Francisco, Josenando, Théophilo, Bernhard, Sonja C., Olson, Carol A., Blum, Johannes, Tidwell, Richard R., Pohlig, Gabriele
Publicado no PLoS Negl Trop Dis (2016)
“.... We conducted two Phase 2 studies to determine the efficacy and safety of oral pafuramidine in African...”Publicado no PLoS Negl Trop Dis (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por Oriol De Fabregues, Jaume Viñas, Antoni Palasí, Manuel Quintana, Ignasi Cardona, Cristina Auger, Víctor Vargas
Publicado em 2020-05-01
Assuntos:
“...safety...”Publicado em 2020-05-01
Obter o texto integral
Artigo
8
Por Callahan, Margaret K., Kluger, Harriet, Postow, Michael A., Segal, Neil H., Lesokhin, Alexander, Atkins, Michael B., Kirkwood, John M., Krishnan, Suba, Bhore, Rafia, Horak, Christine, Wolchok, Jedd D., Sznol, Mario
Publicado no J Clin Oncol (2018)
“... patient who had multiorgan failure 70 days after the last dose of NIVO plus IPI. CONCLUSION...”Publicado no J Clin Oncol (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Hurvitz, Sara A., Gonçalves, Anthony, Rugo, Hope S., Lee, Kyung‐Hun, Fehrenbacher, Louis, Mina, Lida A., Diab, Sami, Blum, Joanne L., Chakrabarti, Jayeta, Elmeliegy, Mohamed, DeAnnuntis, Liza, Gauthier, Eric, Czibere, Akos, Tudor, Iulia Cristina, Quek, Ruben G.W., Litton, Jennifer K., Ettl, Johannes
Publicado no Oncologist (2019)
“...BACKGROUND: In the EMBRACA phase III study (NCT01945775), talazoparib was associated with a...”Publicado no Oncologist (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
“... collected starting immediately prior to dosing until 96 hours after the last dose. Safety was assessed...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
“... with these mechanistic studies, early phase clinical trials using the checkpoint inhibitors nivolumab and pembrolizumab...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Fuchs, Charles S., Doi, Toshihiko, Jang, Raymond W., Muro, Kei, Satoh, Taroh, Machado, Manuela, Sun, Weijing, Jalal, Shadia I., Shah, Manish A., Metges, Jean-Phillipe, Garrido, Marcelo, Golan, Talia, Mandala, Mario, Wainberg, Zev A., Catenacci, Daniel V., Ohtsu, Atsushi, Shitara, Kohei, Geva, Ravit, Bleeker, Jonathan, Ko, Andrew H., Ku, Geoffrey, Philip, Philip, Enzinger, Peter C., Bang, Yung-Jue, Levitan, Diane, Wang, Jiangdian, Rosales, Minori, Dalal, Rita P., Yoon, Harry H.
Publicado no JAMA Oncol (2018)
“... has progressed after 2 or more lines of therapy. OBJECTIVE: To evaluate the safety and efficacy...”Publicado no JAMA Oncol (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Por Burmester, Gerd R, Matucci-Cerinic, Marco, Mariette, Xavier, Navarro-Blasco, Francisco, Kary, Sonja, Unnebrink, Kristina, Kupper, Hartmut
Publicado em 2014
“... to continue treatment for 5 years in ReAlise. The purpose of this study was to evaluate the long-term safety...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por Breedt, Johannes, Teras, Jüri, Gardovskis, Janis, Maritz, Frans Jacobus, Vaasna, Tiit, Ross, Douglas Patrick, Gioud-Paquet, Martine, Dartois, Nathalie, Ellis-Grosse, Evelyn J., Loh, Evan
Publicado em 2005
“... visit 12 to 92 days after the last dose. The microbiologic response at the test-of-cure visit was also...”Publicado em 2005
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Kim, Jae‐Joon, Ryu, Min‐Hee, Yoo, Changhoon, Beck, Mo Youl, Ma, Jung Eun, Kang, Yoon‐Koo
Publicado no Oncologist (2019)
“... control rate (DCR: complete response plus partial response [PR] plus stable disease [SD]) lasting...”Publicado no Oncologist (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Jones, Jeffrey A., Mato, Anthony R., Wierda, William G., Davids, Matthew S., Choi, Michael, Cheson, Bruce D., Furman, Richard R., Lamanna, Nicole, Barr, Paul M., Zhou, Lang, Chyla, Brenda, Salem, Ahmed Hamed, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Coutre, Steven, Woyach, Jennifer, Byrd, John C.
Publicado no Lancet Oncol (2017)
“... the efficacy and safety of venetoclax monotherapy. Efficacy was measured by overall response rate, defined...”Publicado no Lancet Oncol (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Martin-Broto, Javier, Hindi, Nadia, Lopez-Pousa, Antonio, Peinado-Serrano, Javier, Alvarez, Rosa, Alvarez-Gonzalez, Ana, Italiano, Antoine, Sargos, Paul, Cruz-Jurado, Josefina, Isern-Verdum, Josep, Dolado, Maria Carmen, Rincon-Pérez, Inmaculada, Sanchez-Bustos, Paloma, Gutierrez, Antonio, Romagosa, Cleofe, Morosi, Carlo, Grignani, Giovanni, Gatti, Marco, Luna, Pablo, Alastuey, Ignacio, Redondo, Andres, Belinchon, Belen, Martinez-Serra, Jordi, Sunyach, Marie-Pierre, Coindre, Jean-Michel, Dei Tos, Angelo P., Romero, Jesus, Gronchi, Alessandro, Blay, Jean-Yves, Moura, David S.
Publicado no JAMA Oncol (2020)
“...) and the overall response rate (phase 2) with use of trabectedin plus irradiation in metastatic soft-tissue...”Publicado no JAMA Oncol (2020)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Vink, Peter, Torrell, Josep Maria Ramon, Sanchez-Fructuoso, Ana I, Kim, Sung-Joo, Kim, Sang Il, Zaltzman, Jeffrey, Ortiz, Fernanda, Plana, Josep Maria Campistol, Rodriguez, Ana Maria Fernandez, Rodrigo, Henar Rebollo, Marti, Magda Campins, Perez, Rafael, González-Roncero, Francisco Manuel, Kumar, Deepali, Chiang, Yang-Jen, Doucette, Karen, Pipeleers, Lissa, Morales, Maria Luisa Agüera, Ferrero, Maria Luisa Rodriguez, Secchi, Antonio, McNeil, Shelly A, Campora, Laura, Paolo, Emmanuel Di, Idrissi, Mohamed El, López-Fauqued, Marta, Salaun, Bruno, Heineman, Thomas, Oostvogels, Lidia
Publicado no Open Forum Infect Dis (2018)
“... post-last dose safety and immune persistence data are presented. METHODS: In this phase III, 1:1...”Publicado no Open Forum Infect Dis (2018)
Obter o texto integral
Obter o texto integral
Artigo
19
Por Connolly, Lynn E., Riddle, Valerie, Cebrik, Deborah, Armstrong, Eliana S., Miller, Loren G.
Publicado no Antimicrob Agents Chemother (2018)
“... evaluated the efficacy and safety of plazomicin in a double-blind, comparator-controlled, phase 2 study...”Publicado no Antimicrob Agents Chemother (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Mehendale, Sanjay, Thakar, Madhuri, Sahay, Seema, Kumar, Makesh, Shete, Ashwini, Sathyamurthi, Pattabiraman, Verma, Amita, Kurle, Swarali, Shrotri, Aparna, Gilmour, Jill, Goyal, Rajat, Dally, Len, Sayeed, Eddy, Zachariah, Devika, Ackland, James, Kochhar, Sonali, Cox, Josephine H., Excler, Jean-Louis, Kumaraswami, Vasanthapuram, Paranjape, Ramesh, Ramanathan, Vadakkuppatu Devasenapathi
Publicado em 2013
“... vaccinations, the response rate was significantly higher in group A after 1(st) and 2(nd) MVA doses as compared...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo